CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: BoA Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 3:40 p.m. PT TD Cowen’s 6 th... Read More

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1... Read More

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. About Relay Therapeutics Relay... Read More

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib... Read More

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen’s 45 th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ET Barclays... Read More

CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay... Read More

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at... Read More

New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a... Read More

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be... Read More

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors Relay Therapeutics has potential to receive up to $500 million in upfront,... Read More

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors Relay Therapeutics has potential to receive up to $500 million in upfront,... Read More

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc . (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats: Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00... Read More

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Relay... Read More

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay... Read More

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. Relay Therapeutics also... Read More

CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a... Read More

9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet... Read More

Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge... Read More

Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration with Pfizer for combination development of RLY-2608 + fulvestrant + atirmociclib (CDK4i) in PI3Kα-mutated HR+/HER2- metastatic breast cancer, with clinical start planned by end of 2024 Approximately $688 million... Read More

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024. About Relay Therapeutics Relay... Read More

3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage... Read More

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608... Read More

CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen 5th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 28, 2024 at... Read More

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that the company will host a New Program and Platform event on Thursday, June 6, 2024 from 8:00 to 10:00 a.m. ET. During the event, the company will disclose new... Read More

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights. “We have started 2024 with a focus on maintaining strong execution across our portfolio,” said Sanjiv... Read More

CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2, 2024. About Relay Therapeutics Relay... Read More

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m. ET The... Read More

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen’s 44 th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m. ET Leerink... Read More

Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE,... Read More

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024. About Relay... Read More

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30... Read More

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) with Nextech to sell an aggregate of 2.5 million shares of... Read More

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at... Read More

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link:... Read More

Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runway by approximately 1 year Approximately $811 million in cash, cash equivalents and investments at end of Q3 2023, expected to fund operations into... Read More

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 2, 2023. About Relay Therapeutics Relay... Read More

35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to initiate RLY-2608 triplet combinations in HR+/HER2- breast cancer by YE 2023 Pipeline updates extend cash runway by 1 year into 2H2026 Relay Therapeutics to host... Read More

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming... Read More

Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measurable disease achieved a partial response Clinical benefit, including partial responses, observed across PI3Kα mutations and dose levels Approximately... Read More

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 8, 2023. About Relay Therapeutics Relay... Read More

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor... Read More

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in two upcoming fireside chats: TD Cowen 4th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 30, 2023 at 1:00 p.m. ET Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 10:00 a.m. PT The fireside chats will be webcast live and... Read More

Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q1 2023, expected to fund operations into 2025 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage... Read More

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023. The company will not be conducting a... Read More

CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats: Stifel 2023 Targeted Oncology Days, on Wednesday, April 26, 2023 at 12:30 p.m. ET BofA Securities 2023 Health Care Conference, on Tuesday, May 9, 2023 at 10:00 a.m. PT The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under... Read More

Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient with 12 prior lines of therapy Initial anti-tumor activity in breast cancer patients observed across range of doses Relay Therapeutics to host a conference call today,... Read More

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that initial clinical data from the ReDiscover trial for RLY-2608 have been selected for presentation at the upcoming American Association for Cancer Research... Read More

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43 rd Annual Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET and the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:05 p.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics’... Read More

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path Progressed & expanded breast cancer portfolio: Continued monotherapy and initiated combination arms in study of PI3Kα inhibitor RLY-2608 & disclosed 3 new pre-clinical programs Raised $300.0 million of... Read More

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2022 financial results and corporate highlights after the close of market on Thursday, February 23, 2023. The company will not be... Read More

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 9, 2023 at 10:10 a.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link:... Read More

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 2:15 p.m. PT. The presentation will be webcast live and may be... Read More